Source: Annual Congress 2006 - Infections in immunocompromised patients



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gregersen, J. Kongerud, P. Aukrust, S. S. Frøland, B. Johansen (Oslo, Norway). Immunoglobulin treatment with recommended dosages do not prevent deterioration in lung function in primary hypogammaglobulinemia. Eur Respir J 2006; 28: Suppl. 50, 3205

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary immunoglobulin E levels and the response to anti-immunoglobulin E antibody therapy in paediatric severe therapy resistant asthma Source: Annual Congress 2012 - Treating childhood asthma Year: 2012 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Late Breaking Abstract - The respiratory tract of patients with antibody deficiency on immunoglobulin replacement is characterised by inflammation and dysbiosis despite adequate levels of sputum IgG Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes Year: 2021 Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Is it effective to administer corticosteroids late for neonatal chronic lung disease? Source: Eur Respir J 2004; 24: Suppl. 48, 620s Year: 2004 The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 Intravenous α1-antitrypsin in a child with deficiency and severe lung disease Source: Eur Respir J 2009; 34: 278-279 Year: 2009 Serum immunoglobulin level is a useful marker for the risk of opportunistic infection in steroid dependent patients with chronic inflammatory airway diseases Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Periodical therapy with antibiotics preserves lung function in patients with bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020